

研究者主導研究における重点領域（対象疾患：がん）



Ixazomib : ニンラーロ[®]

- Currently not accepting proposals

Brigatinib : アルンブリグ®

- Studies investigating brigatinib in NSCLC, evaluation of CNS activity, rational combinations with other agents/modalities, and sequencing of ALK TKIs

Mobocertinib

- Studies exploring optimal sequencing of epidermal growth factor receptor (EGFR) inhibitors in Exon 20 insertion mutated NSCLC
- Combination studies with mobocertinib in patients with EGFR exon 20 insertion mutated NSCLC, utilizing agents with a clear scientific rationale
- Studies focusing on characterizing and managing Adverse Events (AEs) associated with mobocertinib (mainly GI toxicity, associated mechanisms of cardiac toxicity) including studies that investigate alternate dosing schedules in patients treated with mobocertinib
- Real-World Data (RWD) to evaluate disease state, efficacy and safety of current treatment options and treatment patterns of NSCLC patients with EGFR exon 20 insertion mutations
- Studies that address CNS metastases by exploring different modalities to target CNS disease in patients treated with mobocertinib

Out of Scope

- Studies of mobocertinib in pediatric populations

Brentuximab vedotin : アドセトリス®

- Studies which evaluate reversibility of peripheral neuropathy

Cabozantinib：カボメティクス®

- 固形癌における標準治療不応後の検討
- 腎細胞がんに対する効果予測因子や新規併用療法の検討
- 肝細胞がんに対する治療実態の検討
- 副作用マネジメントの検討

Niraparib：ゼジューラ®

- PARP阻害剤や白金系抗悪性腫瘍剤抵抗性克服に関する検討
- アドヒアランス向上や適正使用推進に関する検討
- 卵巣癌、PARP阻害剤に対する効果予測因子や新規併用療法の検討
- 固形癌における標準治療不応後の検討

研究者主導研究における重点領域（対象疾患：がん）



Panitumumab : ベクティビックス®

現在募集しておりません